Characterization of mutations in lung fibrosis patients
Ulla Hodgson (HYKS, Sydän- ja Keuhkokeskus)
We try to identify mutations in blood and lung tissue samples in patients who have undergone pulmonary transplantation due to idiopathic lung fibrosis (IPF), and evaluate whether the mutations affect the post-transplantation changes in blood count. By identifying the mutations we might be able to understand the occurrence and progression of the disease.
Prevalence and prognostic factors of mesothelioma
Eva Sutinen and Marjukka Myllärniemi (HUS)
In our study, we aim to investigate the prevalence and clinical prognostic factors of somatic and germline mutations in malignant pleural mesothelioma. We investigate the behavior of the disease at the cellular level and seek markers that help to identify the disease earlier and predict the nature of the disease. In addition, the samples can be used to determine genetic factors and their effects on health.
Quality Registry and Biobank for Thoracic Malignancies
Marjukka Myllärniemi, Ilkka Ilonen and Jari Räsänen (University of Helsinki, HUS)
The aim of the study is identify biomarkers for thoracic malignancies in order to help with baseline diagnosis and treatment responses and therefore identify patients who would benefit from different treatments.
Molecular profiling of idiopathic pulmonary fibrosis
Marjukka Myllärniemi (University of Helsinki)
The aim of the study is to elucidate novel molecular mechanisms behind Idiopathis pulmonary fibrosis (IPF) in a well-characterized Finnish patient cohort. Blood samples from 23 patients with IPF will be compared to age- and gender matched blood samples from non-IPF patients in order to identify the IPF specific protein changes in the blood.
Lasten diffuusien keuhkosairauksien HRTT-löydökset -hanke
Laura Martelius (HUS)
The aim of the study is to survey the amount of diffuse lung diseases diagnosed by lung biopsy in children to whom a HRCT (High-resolution computed tomography) examination have been conducted in the HUS Children's hospital, and to document disease specifically the findings from the HRCT-examinations.
Biomarkkerit keuhkon karsinoidituumoreissa
Johanna Arola and Tiina Vesterinen (University of Helsinki)
By analysing tissue samples and related clinical data collected from Finnish pulmonary carcinoid patients the aim is to find new, or validate already found, diagnostic, predictive and/or prognostic markers for pulmonary carcinoids. The long-term objective is to improve diagnostics, prediction and prognostic evaluation of pulmonary carcinoid patients.
Comprehensive Primary Lung Tumour Analysis to Evaluate Precision Medicine Opportunities
Emmy Verschuren (Institute for Molecular Medicine Finland FIMM)
The aim of the project is to investigate lung cancer histotype-specific immune markers. Immunostaining results will be correlated with clinical features of the patients such as co-existence of inflammatory diseases, clinical treatments, and tumor stage results.